The Global RNA Interference Therapeutics Market was valued at USD 4.2 billion in 2025 and is estimated to grow at a CAGR of 18.5% to reach USD 31.4 billion by 2035.
The RNA interference therapeutics market is witnessing strong expansion as advances in genetic science, growing disease burden, and increasing focus on precision medicine continue to reshape modern drug development. RNAi-based therapies are gaining momentum due to their ability to selectively silence disease-causing genes, offering targeted treatment options for complex genetic and chronic conditions. Rising prevalence of rare genetic disorders and metabolic diseases is further accelerating demand for innovative gene-silencing therapies. Continuous improvements in molecular biology, RNA delivery systems, and drug design are enhancing therapeutic performance and clinical applicability. The integration of advanced delivery platforms has significantly improved targeting accuracy, stability, and safety profiles, supporting broader clinical adoption. Pharmaceutical companies are increasingly investing in RNA-based research programs to expand treatment applications across multiple therapeutic areas. Growing regulatory support for orphan and precision medicines is also contributing to faster development timelines and commercialization opportunities. These factors collectively support strong long-term growth potential across the global RNA interference therapeutics market.
The hereditary transthyretin-mediated amyloidosis (hATTR) segment accounted for 35.7% share in 2025 and is expected to reach USD 10.9 billion by 2035. This segment continues to lead due to rising diagnostic rates and the availability of approved RNAi-based treatment options targeting the condition. hATTR is a genetic disorder caused by mutations in the transthyretin gene, resulting in abnormal protein buildup that affects multiple organs and leads to progressive complications over time. Increasing clinical recognition and treatment adoption continue to support segment growth.
The subcutaneous administration segment is projected to grow at a CAGR of 18.6% through 2035. This route of administration is widely preferred due to its convenience, reduced need for clinical supervision, and improved patient adherence compared to intravenous methods. The adoption of advanced conjugation technologies has enabled efficient targeted delivery through subcutaneous injection, improving therapeutic outcomes while reducing systemic exposure and associated side effects. These advantages continue to reinforce the dominance of this delivery approach in RNAi-based treatments.
North America RNA Interference Therapeutics Market accounted for 72% share in 2025, due to strong clinical adoption, advanced healthcare infrastructure, and favorable regulatory frameworks supporting rare disease therapies. The region benefits from early access to approved RNAi-based medicines and a well-established biotechnology ecosystem that supports ongoing research and commercialization. Continuous investment in genetic research and expanding clinical capabilities further strengthen North America’s dominance in the global market.
Major companies operating in the global RNA interference therapeutics market include Novartis, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Sanofi, Novo Nordisk, Silence Therapeutics, Sirnaomics, Arbutus Biopharma, Benitec Biopharma, OliX Pharmaceuticals, and Atalanta Therapeutics. Companies operating in the RNA interference therapeutics market are strengthening their market position through continuous investment in RNA technology platforms, advanced delivery systems, and precision medicine development. Market participants are expanding clinical pipelines across multiple disease areas while improving molecular design strategies to enhance stability, efficacy, and targeting accuracy. Strategic collaborations with biotechnology firms, academic institutions, and research organizations are accelerating innovation and reducing development timelines. Companies are also focusing on scaling manufacturing capabilities to support commercial demand and ensure consistent product quality. In addition, increasing emphasis on targeted delivery technologies, regulatory approvals, and global expansion strategies is enabling firms to broaden their market reach, strengthen competitive positioning, and build long-term leadership in the RNA interference therapeutics market.
This product will be delivered within 2-4 business days.
The RNA interference therapeutics market is witnessing strong expansion as advances in genetic science, growing disease burden, and increasing focus on precision medicine continue to reshape modern drug development. RNAi-based therapies are gaining momentum due to their ability to selectively silence disease-causing genes, offering targeted treatment options for complex genetic and chronic conditions. Rising prevalence of rare genetic disorders and metabolic diseases is further accelerating demand for innovative gene-silencing therapies. Continuous improvements in molecular biology, RNA delivery systems, and drug design are enhancing therapeutic performance and clinical applicability. The integration of advanced delivery platforms has significantly improved targeting accuracy, stability, and safety profiles, supporting broader clinical adoption. Pharmaceutical companies are increasingly investing in RNA-based research programs to expand treatment applications across multiple therapeutic areas. Growing regulatory support for orphan and precision medicines is also contributing to faster development timelines and commercialization opportunities. These factors collectively support strong long-term growth potential across the global RNA interference therapeutics market.
The hereditary transthyretin-mediated amyloidosis (hATTR) segment accounted for 35.7% share in 2025 and is expected to reach USD 10.9 billion by 2035. This segment continues to lead due to rising diagnostic rates and the availability of approved RNAi-based treatment options targeting the condition. hATTR is a genetic disorder caused by mutations in the transthyretin gene, resulting in abnormal protein buildup that affects multiple organs and leads to progressive complications over time. Increasing clinical recognition and treatment adoption continue to support segment growth.
The subcutaneous administration segment is projected to grow at a CAGR of 18.6% through 2035. This route of administration is widely preferred due to its convenience, reduced need for clinical supervision, and improved patient adherence compared to intravenous methods. The adoption of advanced conjugation technologies has enabled efficient targeted delivery through subcutaneous injection, improving therapeutic outcomes while reducing systemic exposure and associated side effects. These advantages continue to reinforce the dominance of this delivery approach in RNAi-based treatments.
North America RNA Interference Therapeutics Market accounted for 72% share in 2025, due to strong clinical adoption, advanced healthcare infrastructure, and favorable regulatory frameworks supporting rare disease therapies. The region benefits from early access to approved RNAi-based medicines and a well-established biotechnology ecosystem that supports ongoing research and commercialization. Continuous investment in genetic research and expanding clinical capabilities further strengthen North America’s dominance in the global market.
Major companies operating in the global RNA interference therapeutics market include Novartis, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Sanofi, Novo Nordisk, Silence Therapeutics, Sirnaomics, Arbutus Biopharma, Benitec Biopharma, OliX Pharmaceuticals, and Atalanta Therapeutics. Companies operating in the RNA interference therapeutics market are strengthening their market position through continuous investment in RNA technology platforms, advanced delivery systems, and precision medicine development. Market participants are expanding clinical pipelines across multiple disease areas while improving molecular design strategies to enhance stability, efficacy, and targeting accuracy. Strategic collaborations with biotechnology firms, academic institutions, and research organizations are accelerating innovation and reducing development timelines. Companies are also focusing on scaling manufacturing capabilities to support commercial demand and ensure consistent product quality. In addition, increasing emphasis on targeted delivery technologies, regulatory approvals, and global expansion strategies is enabling firms to broaden their market reach, strengthen competitive positioning, and build long-term leadership in the RNA interference therapeutics market.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Indication, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Route of Administration, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
- Alnylam Pharmaceuticals
- Novartis
- Novo Nordisk
- Sanofi
- Arrowhead Pharmaceuticals
- Silence Therapeutics
- Sirnaomics
- Arbutus Biopharma
- Benitec Biopharma
- OliX Pharmaceuticals
- Atalanta Therapeutics
